Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol

Last updated: September 3, 2021
Sponsor: Ultromics Ltd
Overall Status: Active - Enrolling

Phase

N/A

Condition

Cancer

Treatment

N/A

Clinical Study ID

NCT04877899
COL-04
  • Ages > 18
  • All Genders

Study Summary

This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Normal EF and no regional wall motion abnormalities prior to starting chemotherapytreatment.
  • Follow-up EF measurements available for at least 1 year during the treatment period.
  • Follow-up EF measurements for at least 1 year during the treatment period.

Exclusion

Exclusion Criteria:

  • Age < 18 years
  • Inadequate image quality (as determined by the Ultromics Operators Quality Controlprocess)

Study Design

Total Participants: 250
Study Start date:
October 08, 2020
Estimated Completion Date:
November 30, 2021

Connect with a study center

  • Mazankowski Alberta Heart Institute

    Edmonton, Alberta T6G 2J2
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.